(NYSE: TEVA) Teva Pharmaceutical Industries's forecast annual revenue growth rate of 1.94% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.24%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.77%.
Teva Pharmaceutical Industries's revenue in 2025 is $16,616,000,000.On average, 3 Wall Street analysts forecast TEVA's revenue for 2025 to be $19,458,269,137,743, with the lowest TEVA revenue forecast at $19,346,689,442,169, and the highest TEVA revenue forecast at $19,593,721,655,739. On average, 5 Wall Street analysts forecast TEVA's revenue for 2026 to be $19,687,827,417,922, with the lowest TEVA revenue forecast at $19,376,625,094,385, and the highest TEVA revenue forecast at $20,331,182,433,708.
In 2027, TEVA is forecast to generate $20,235,668,204,823 in revenue, with the lowest revenue forecast at $19,465,285,091,176 and the highest revenue forecast at $21,128,147,488,955.